Insider Trading November 21, 2026 07:01 PM

Regeneron EVP Marion McCourt Offloads $543,504 in Stock Under Prearranged Plan

The commercial chief's sale comes as shares hover near a 52-week high, following a 44% six-month rally.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
REGN

Marion McCourt, Executive Vice President Commercial at Regeneron Pharmaceuticals (NASDAQ:REGN), sold 566 shares of common stock on November 16, 2026, for a total of $543,504. The shares were sold at prices between $952.79 and $971.93. The transaction was executed under a Rule 10b5-1 trading plan adopted on February 17, 2026. Following the sale, McCourt directly holds 10,305 shares and indirectly holds 219 shares through a 401(k) plan. Regeneron stock is trading near its 52-week high of $991.73 after a 44% gain over the past six months, and the company, valued at $92.66 billion, recently reported a 35% sales increase for Dupixent in Q3 2026, along with FDA approval for Livsayis and several analyst price target increases.

Regeneron EVP Marion McCourt Offloads $543,504 in Stock Under Prearranged Plan
REGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Marion McCourt, EVP Commercial at Regeneron, sold 566 shares for $543,504 under a Rule 10b5-1 plan adopted in February 2026, leaving her with 10,305 directly held shares and 219 indirectly held through a 401(k).
  • The sale comes as Regeneron stock trades near its 52-week high of $991.73, after a 44% gain over the past six months, with shares recently at $920.69 and a market valuation of $92.66 billion.
  • Dupixent sales rose 35% to $6.54 billion in Q3 2026, driving analyst price target increases from Argus, Cantor Fitzgerald, Truist, TD Cowen, and Jefferies, while FDA approval of Livsayis and a patent hearing for EYLEA HD add to the company's product momentum.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) disclosed that Marion McCourt, the company's Executive Vice President Commercial, sold 566 shares of common stock on November 16, 2026, according to a regulatory filing. The shares were sold at prices ranging from $952.79 to $971.93, resulting in a total transaction value of $543,504.

The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which McCourt adopted on February 17, 2026. Such plans allow company insiders to set up predetermined schedules for buying or selling stock, providing a defense against allegations of trading on material nonpublic information.

Following the transaction, McCourt directly holds 10,305 shares of Regeneron common stock. In addition, she indirectly holds 219 shares through a 401(k) plan.

The sale occurred as Regeneron shares trade near their 52-week high of $991.73. The stock has gained 44% over the past six months. According to an analysis, the stock remains undervalued, with shares recently trading at $920.69 and the company carrying a market valuation of $92.66 billion.

In other recent developments, Regeneron reported significant progress in its financial and product portfolio. Dupixent, the company's leading revenue-generating product, saw a 35% increase in sales during the third quarter of 2026, reaching $6.54 billion. This strong performance led Argus to raise its price target for Regeneron shares to $1,050 while maintaining a Buy rating. Cantor Fitzgerald also increased its price target to $980, highlighting Dupixent's contribution to Sanofi collaboration revenue, which reached $2.72 billion.

Additionally, Regeneron received FDA approval for Livsayis (cemdisiran) for treating generalized myasthenia gravis. This approval prompted Truist Securities to reiterate a Buy rating with a $982 price target. TD Cowen maintained its Buy rating and $980 price target following the approval, emphasizing the treatment's REMS and vaccination requirements. Meanwhile, Jefferies reiterated a Buy rating with a $1,065 price target in anticipation of a Patent Trial and Appeal Board hearing on Regeneron's EYLEA HD '036 patent, which could extend protection until 2039.

These developments reflect the company's robust performance and strategic advancements in its product offerings.

Risks

  • The sale was executed under a prearranged Rule 10b5-1 plan, which may not reflect McCourt's current view of the company's prospects, but insider selling can still be interpreted by some investors as a signal of reduced confidence.
  • Regeneron's stock is trading near its 52-week high, and any pullback could amplify negative sentiment, particularly given the company's reliance on Dupixent for a significant portion of revenue.
  • The outcome of the Patent Trial and Appeal Board hearing on the EYLEA HD '036 patent is uncertain and could affect the duration of market exclusivity for a key product.

More from Insider Trading

Texas Community Bancshares COO Haskell Strange Offloads $14,911 in Stock Nov 21, 2026 Amphastar CFO Offloads $330K in Shares Under Pre-Set Trading Plan Nov 21, 2026 Park-Ohio CFO Offloads $99,213 in Stock Under Pre-Arranged Plan Nov 21, 2026 Runway Growth Finance CFO Carmela Thomson Buys $6,670 in Stock Nov 21, 2026 CION Investment Corp President Buys $48,110 in Stock Near 52-Week Low Nov 21, 2026